BI 1820237 / Boehringer Ingelheim - LARVOL DELTA

Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide. (PubMed, Mol Metab) - "Regression-based interaction analysis demonstrated that BI 1820237 increased the efficacy of survodutide by 265% at an ED50 of 11.7 nmol/kg over a range of dose combinations. Synergistic NPY2R and GCGR/GLP-1R agonism provides an attractive mode of action for clinically relevant weight loss in patients with obesity."

Journal • Genetic Disorders • Obesity

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity (clinicaltrials.gov) - P1 | N=23 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity. (PubMed, Diabetes Obes Metab) - P1 | "BI 1820237 treatment was associated with transient nausea and vomiting at higher doses. No differences in tolerability were observed when combined with liraglutide; effects on gastric emptying appeared additive."

Combination therapy • Journal • P1 data • Gastrointestinal Disorder • Genetic Disorders • Obesity

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 (clinicaltrials.gov) - P1 | N=88 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed | N=30 ➔ 88

Combination therapy • Enrollment change • Trial completion • Genetic Disorders • Obesity

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial • Genetic Disorders • Obesity

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Apr 2024 ➔ Jul 2024 | Trial primary completion date: Apr 2024 ➔ Jul 2024

Combination therapy • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Recruiting | N=30 ➔ 92

Enrollment change • Enrollment open • Genetic Disorders • Obesity

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting | N=92 ➔ 30

Combination therapy • Enrollment change • Enrollment closed • Genetic Disorders • Obesity

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Genetic Disorders • Obesity

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 (clinicaltrials.gov) - P1 | N=92 | Not yet recruiting | Sponsor: Boehringer Ingelheim

Combination therapy • New P1 trial • Genetic Disorders • Obesity